Home

  • Order to parcel locker

    Order to parcel locker

  • easy pay

    easy pay
  • Reduced price
  • New
50 Studies Every Endocrinologist Should Know

50 Studies Every Endocrinologist Should Know

Classic Endocrinology

9780197684702
414.18 zł
372.76 zł Save 41.42 zł Tax included
Lowest price within 30 days before promotion: 372.76 zł
Quantity
Teaser
2026-01-17

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DHL, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
50 Studies Every Endocrinologist Should Know assembles landmark, evidence-based studies in classic endocrinology to guide readers towards solving thorny endocrine problems. Featuring a diverse range of study types-including RCTs, multicenter trials, observational studies, and meta-analyses-this volume addresses the core issues faced by endocrinologists in clinical practice. Each chapter provides a concise summary of key studies, highlighting results, limitations, andpractical implications. The chapters conclude with a list of major take-home points, which collectively form a foundation of Endocrine Principles that can be applied to real-word patient problems. As with all books in the 50 Studies series, each study was sel‎ected using an objective selection criterion that included citations per year, high levels of evidence, clinical studies and trials, and a 3-stage Delphi review by international experts in the field. It is an indispensable reference for fellows, physicians, nurse practitioners, and any primary providers with an interest in endocrinology, as well as those taking both the endocrinology board exam and the Endocrinology, Diabetes,& Metabolism certification exam.
Product Details
OUP USA
104094
9780197684702
9780197684702

Data sheet

Publication date
2026
Issue number
1
Cover
paperback
Pages count
424
Dimensions (mm)
156 x 235
  • SECTION 1: Conditions caused by Thyroid Damage; Chapter 1: Screening for Thyroid Disease in Early Pregnancy and in Pre-Pregnancy; Chapter 2: Subclinical Hypothyroidism; Chapter 3: Management of Thyroxine in Non-Ablated Patients with Hypothyroidism; Chapter 4: Optimal Thyroid Replacement for the Athyreotic Patient; SECTION 2: Conditions Causing Thyroid Overactivity ; Chapter 5: Antithyroid Drugs vs. Ablation in Community Treatment for Graves Disease; Chapter 6: Optimum Use of Antithyroid Drugs in Hyperthyroidism; Chapter 7: Risks of I-131 Treatment of Hyperthyroidism; Chapter 8: Hyperthyroidism caused by Amiodarone (AIT); SECTION 3: Focal and Structural Thyroid Disease; Chapter 9: Selection of Thyroid Nodules to be Biopsied; Chapter 10: Selection of Patients over 45 for Thyroid Biopsy; Chapter 11: Molecular Genomic Testing (MGT) for Indeterminate Thyroid Nodules; Chapter 12: Complication Rate(s) from Thyroidectomy; Chapter 13: Ablation Techniques for Benign or Hot Nodules; Chapter 14: Microscopic Papillary Thyroid Carcinoma (mPTC) and Active Surveillance (AS); Chapter 15: Optimal Work-up and Surgery for a small, non-metastatic DTCA; Chapter 16: I-131 Treatment for DTCA; SECTION 4: Parathyroid Diseases; Chapter 17: Active Surveillance and/or Medical Therapy for Hyperparathyroidism in Older Patients; Chapter 18: Preoperative Localization of Sporadic Primary Hyperparathyroidism; Chapter 19: Quality of Life after Surgery for Mild/Moderate Sporadic Primary Hyperparathyroidism; Chapter 20: Secondary Hyperparathyroidism, Idiopathic Hypercalciuria, and Bone Density; Chapter 21: Recurrent and/or Persistent Primary Hyperparathyroidism; SECTION 5: Metabolic Bone Disease; Chapter 22: Calcium and Vitamin D Effects on Bone Mass; Chapter 23: Fracture Prevention in Patients with Low Bone Mass; Chapter 24: Pretreatment Evaluation for Osteoporosis; Chapter 25: Evaluation of Fracture Risk in Osteoporosis; Chapter 26: Osteoporosis and Hip Fracture Prevention; Chapter 27: Alendronate and Fracture Risk Reduction; Chapter 28: Hip Fracture in the Elderly with Very Low Bone Density; Chapter 29: Anabolic Agent(s) for Osteoporosis; Chapter 30: Glucocorticoid Osteoporosis; Chapter 31: Osteoporosis in Men; SECTION 6: Adrenal Conditions; Chapter 32: The Importance of Recognizing Hyperaldosteronism; Chapter 33: Effectiveness of Treatment of Hyperaldosteronism; Chapter 34: Screening for Adrenal Insufficiency; Chapter 35: Adrenal Incidentalomas; Chapter 36: Opioid-Induced Endocrine Deficiencies; Chapter 37: Adrenal Insufficiency from Corticosteroid Treatment; Chapter 38: Optimal Testing for ACTH-Dependent Hypercortisolism; SECTION 7: Pituitary Tumors / Hypercortisolism; Chapter 39: Duration of Medical Treatment of Intrasellar Prolactinomas; Chapter 40: Acromegaly Treatment-Surgery, Medication, or What?; Chapter 41: Primary Treatment of Pituitary Hypercortisolism; Chapter 42: Treatment of Recurrent or Persistent Hypercortisolism; SECTION 8: Conditions Caused by Testosterone Deficiency; Chapter 43: Risks of Testosterone Treatment in Older Men; Chapter 44: Male Obesity Secondary Hypogonadism (MOSH); SECTION 9: Conditions Related to Estrogen Deficiency ; Chapter 45: Estrogen Treatment and Cardiovascular Health; Chapter 46: Estrogen Treatment and Skeletal Health; Chapter 47: Estrogen + Progestin vs. Estrogen Alone, and Neoplasia; SECTION 10: Polycystic Ovary Syndrome; Chapter 48: Optimal Differential Diagnosis of PCOS; Chapter 49: Optimal Treatment of Hirsutism in PCOS; Chapter 50: Treatment of Subfertility in PCOS;
Comments (0)
Viewed products

  • Frequently purchased together

    No products available